Streetbeat News

Regulatory

SBET

SharpLink Gaming Ltd. (NASDAQ:SBET) CEO Rob Phythian issued a letter to shareholders outlining the company's growth strategies and key performance indicators. The company aims to have a profound impact on the U.S. sports betting industry by improving methods for reaching and converting sports fans into sports bettors. SharpLink has focused on acquiring an affiliate marketing company, completing a merger with SportsHub, and expanding its technology development team. The company's internal KPIs align with each component of its C4 solution: Connect, Collect, Convert, and Capitalize. SharpLink is licensed to operate in 24 U.S. states, the District of Columbia, Puerto Rico, and Ontario, Canada.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:38 pm

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) has praised the U.S. Centers for Disease Control and Prevention's (CDC) new Hospital Sepsis Program Core Elements, aimed at improving sepsis programs and survival rates in U.S. hospitals. T2 Biosystems' products, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel, are the first and only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood in 3-5 hours. The company's products identified sepsis-causing pathogens 77 hours faster than blood culture-based protocols, according to a meta-analysis of 14 controlled studies.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:37 pm

NAOV

NanoVibronix, Inc. (NASDAQ:NAOV) has applied for inclusion of its UroShield products in the National Health Service (NHS) Prescription Services' Drug Tariff in the UK. If approved, the listing would enable reimbursement and increased distribution for NHS patients. The company's CEO, Brian Murphy, believes that the inclusion would allow UroShield technology to be reimbursed and gain broader distribution through pharmacies.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:37 pm

NTIP

Network-1 Technologies, Inc. (NTIP) has received a new eSIM patent titled 'Key Derivation For A Module Using An Embedded Universal Integrated Circuit Card' from the U.S Patent Office. The patent number is 11,736,283.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:35 pm

OCX

Oncocyte Corporation's (NASDAQ:OCX) VitaGraft Kidney diagnostic test has received a positive coverage decision from Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS). The test is designed to identify signs of graft damage in kidney transplant patients. Initial revenue from the service lab business is expected to begin in Q1 2024. Oncocyte's second transplant test, VitaGraft Liver, remains under review for coverage at MolDX.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:34 pm

ANIX

Anixa Biosciences has announced the treatment of the third patient in its ovarian cancer CAR-T clinical trial. This marks a significant step in the company's ongoing research and development efforts in the field of cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:33 pm

NBIX

Neurocrine Biosciences has presented new data on its INGREZZA capsules at the 2023 MDS International Congress of Parkinson's Disease and Movement Disorders. The data shows early and sustained improvements in chorea associated with Huntington's disease.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:32 pm

IMGN

TAK

ImmunoGen (NASDAQ:IMGN) has signed an agreement with Takeda Pharmaceutical (NYSE:TAK) to develop and commercialize the ovarian cancer drug ELAHERE in Japan. ImmunoGen will receive $34 million in upfront and near-term milestone payments and is also eligible for potential regulatory and commercial milestone payments. ImmunoGen retains exclusive production rights and will supply the product for development and commercial use in Japan, while Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan.

Portfolio Pulse from Nabaparna Bhattacharya

August 28, 2023 | 12:22 pm

BIVI

BioVie Inc. (NASDAQ:BIVI) presented new preclinical and Phase 2a study data for its drug NE3107 at the 2023 International Congress of Parkinson's Disease and Movement Disorders. The data supports the potential of NE3107 as a co-administration with carbidopa/levodopa and as a first-line therapy in Parkinson's Disease. The company also announced that it is looking forward to the topline data readout from its Phase 3 Alzheimer's trial later this fall.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:09 pm

LCFY

Locafy Limited (NASDAQ:LCFY) has been granted an exception to Nasdaq Listing Rule 5550(b)(1) regarding the minimum stockholders' equity required for continued listing on Nasdaq until October 31, 2023, subject to certain conditions. The company believes it has regained compliance with the Stockholders' Equity Requirement due to cost-cutting measures and capital allocation prioritization efforts. It also announced a promising Keystone SEO technology agreement with a U.S.-based media publisher.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:07 pm